Rechercher des études
Résultats de recherche
The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.
Conditions:
Red Blood Cell TransfusionEmplacement:
- Hamilton General Hospital, Hamilton, Ontario, Canada
- St. Boniface Hospital, Winnipeg, Manitoba, Canada
- Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
- Montreal Heart Institute, Montreal, Quebec, Canada
Sexe:
ALLÂges:
10 - 110The goal of this study is to determine whether a randomized controlled trial using oropharyngeal exercises to treat sleep apnea is feasible. Continuous positive airway pressure (CPAP) is the standard therapy for Obstructive sleep apnea (OSA), but it is poorly tolerated by many patients. Oropharyngeal exercises (OPEs) which are commonly used by speech-language pathologists to improve oro-motor strength, may serve as a promising alternative approach. The main questions this study aims to answer are: * Is it feasible to use an oropharyngeal exercise protocol in patients with sleep apnea? * Will oropharyngeal exercises improve sleep apnea severity, daytime sleepiness, sleep quality, mood, workplace performance, and quality of life Participants will be randomized into a supervised OPE intervention arm vs. unsupervised OPE intervention arm vs. sham treatment for a 10-week/5-day per week/two 20-minute session exercise protocol. The exercises will be administered via an app and the investigators will assess feasibility, as well as several sleep-related and oro-motor physiological outcomes before treatment, immediately post-treatment, and 4 weeks post-treatment. The investigators will use the results of this feasibility trial to inform the sample size needed for a larger clinical trial that will determine the efficacy of using oropharyngeal exercises to treat OSA.
Conditions:
Obstructive Sleep ApneaEmplacement:
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Sexe:
ALLÂges:
Over 18The goal of this randomized controlled trial is to evaluate the effectiveness of inhaled methoxyflurane (Penthrox) as an analgesic for patients undergoing minor rhinology and sinus procedures, specifically comparing it to a placebo control. The primary question the study aims to answer is: Does methoxyflurane provide superior pain relief compared to placebo during minor sinus procedures, as measured by the Visual Analog Scale (VAS)? If there is a comparison group: Researchers will compare the effects of Penthrox to the placebo (saline + one drop of methoxyflurane) to see if it provides better pain relief, reduces anxiety, and leads to fewer complications, including bleeding. Participants will be asked to: Inhale 3 mL of Penthrox or placebo during their procedure. Complete a VAS scale to assess pain. Complete anxiety assessments pre- and post-operatively. Be monitored for complications such as bleeding and other adverse effects. This study will help determine the effectiveness of Penthrox as a non-invasive, quick-acting analgesic for minor sinus surgeries.
Conditions:
Chronic Rhinosinusitis (CRS)Emplacement:
- St Paul's Sinus Centre, Vancouver, British Columbia, Canada
Sexe:
ALLÂges:
Over 19The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients. The main questions it aims to answer are whether an ML model predicting the risk of vomiting within the next 96 hours will: Primary 1\. Reduce the proportion with any vomiting within the 96-hour window Secondary 1. Reduce the number of vomiting episodes 2. Increase the proportion receiving care pathway-consistent care 3. Impact on number of administrations and costs of antiemetic medications Newly admitted participants will have a ML model predict the risk of vomiting within the next 96 hours according to their medical admission information. The prediction will be made at 8:30 AM following admission. Pharmacists will be charged with bringing information about patients' vomiting risk to the attention of the medical team and implementing interventions.
Conditions:
Pediatric Cancer | Chemotherapy Induced Nausea and Vomiting | Quality of Life (QOL)Emplacement:
- The Hospital for Sick Children, Toronto, Ontario, Canada
Sexe:
ALLÂges:
AnyThe goal of this clinical trial (the SIMPLY-SNAP trial) is to compare a simplified layered consent form to a full-length consent form for use during the informed consent process for a larger clinical trial of treatment of Staphylococcus aureus bloodstream infection (the SNAP trial). The main questions it aims to answer are: * Does use of a simplified layered consent form lead to an increased recruitment rate to the SNAP trial? * Does use of a simplified layer consent form lead to increased participant understanding of the SNAP trial and increased participant satisfaction with the informed consent process? Participants will be randomized to either the full-length informed consent form or the simplified layered consent form containing links to optional supplementary information or videos. Research staff will use the assigned form to explain the SNAP trial to participants. After consent, participants will be evaluated on their understanding of the SNAP trial and satisfaction with the consent process using a questionnaire.
Conditions:
Staphylococcus Aureus BacteremiaEmplacement:
- Michael Garron Hospital, Toronto, Ontario, Canada
- Royal Victoria Hospital, Québec, Quebec, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Montreal General Hospital, Montreal, Quebec, Canada
- The Ottawa Hospital, Ottawa, Ontario, Canada
- Toronto General Hospital, Toronto, Ontario, Canada
- Hamilton General Hospital, Hamilton, Ontario, Canada
- Mount Sinai Hospital, Toronto, Ontario, Canada
- University of Calgary, Foothills Medical Centre, Peter Lougheed Centre, Rockyview Hospital, South Health Campus, Calgary, Alberta, Canada
Sexe:
ALLÂges:
AnyThe investigation is a small feasibility study to determine whether there are imaging features related to the seminiferous tubules in the testes under microultrasound. The results from this study will provide guidance on the design and power analysis of future studies in this area.
Conditions:
AzoospermiaEmplacement:
- University of Alberta, Edmonton, Alberta, Canada
Sexe:
MALEÂges:
Over 18The goal of this open label study is to evaluate the efficacy of smart phone-based test (SOBEREYE OPTOVERA) on measuring pupillary light reflex (PLR) alterations following cannabis use healthy in adults. The main question it aims to answer is: Can SOBEREYE OPTOVERA detect PLR alterations following cannabis consumption in healthy adults, in comparison to a pupillometer? Participants will be given two 5 mg capsules to be ingested for the 10 mg THC dose or five 5 mg capsules to be ingested for the 25 mg THC. Participants will be asked to complete PLR tests throughout the study day.
Conditions:
Cannabis Intoxication | Drug EffectsEmplacement:
- KGK Science Inc., London, Ontario, Canada
Sexe:
ALLÂges:
Over 21This is a prospective, open-label, within-patient clinical trial to determine the accuracy of Indocyanine green (ICG) guided sentinel lymph node biopsy (SLNB) compared to the standard dual-tracer SLNB in breast cancer patients who have had chemotherapy as a first treatment using a non-inferiority design. Patients with operable breast cancer treated with chemotherapy and eligible for SLNB will be included in the study. During surgery, ICG will be injected and used to identify fluorescent sentinel nodes using a hand-held imaging camera; radiotracer and blue dye will also be used as per standard protocols. Intraoperative and clinicopathologic outcomes such as complications, characteristics of nodes, false negative rates and feasibility will be assessed. Patients will be asked to complete standardized patient reported outcome questionnaires (Breast-Q, FACT-B+4, VAS) to define the patient experience with this novel technique.
Conditions:
Breast CancerEmplacement:
- University Health Network, Toronto, Ontario, Canada
Sexe:
ALLÂges:
18 - 80To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Conditions:
Soft Tissue SarcomaEmplacement:
- McGill University Health Centre (Quebec), Montreal, Quebec, Canada
- UHN - Princess Margaret Cancer Center (Ontario), Toronto, Ontario, Canada
Sexe:
ALLÂges:
18 - 99This project aims to study an innovative intervention, the eG2 Intervention, developed by speech-language pathologists at the Centre hospitalier de l'Université de Montréal to improve therapeutic adherence and prevent dysphagia in patients treated with chemoradiotherapy for head and neck cancer. The innovation consists in offering a speech therapy intervention that is 1) virtual, 2) group-based (whereas it is usually individual) and 3) involves a patient partner. This intervention has the potential to improve quality of care, accessibility to services and optimize health care resources.
Conditions:
DysphagiaEmplacement:
- Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada